Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment

Approximately 213,380 new cases of non-small-cell lung cancer (NSCLC) were estimated to occur in the USA in 2007, which caused 160,390 NSCLC-related deaths. The majority of patients will be diagnosed with nonoperable, advanced-stage disease. Although combination chemotherapy remains the standard tre...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Expert review of respiratory medicine 2008-04, Vol.2 (2), p.167-178
Hauptverfasser:	Schettino, Clorinda, Bareschino, Maria Anna, Ricci, Vincenzo, Ciardiello, Fortunato
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer Chemotherapy Development and progression Drug therapy Drug therapy, Combination EGF receptor pathways Epidermal growth factor Erlotinib Lung cancer Lung cancer, Non-small cell Monoclonal antibodies non-small-cell lung cancer Phenols Respiratory agents Tumors Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!